The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -33,887 |
| Stock-based compensation expense | 9,190 |
| Depreciation expense | 173 |
| Amortization of right-of-use assets | 648 |
| Prepaid expenses and other current assets | -219 |
| Accounts payable and accrued expenses | -346 |
| Operating lease liabilities | -577 |
| Net cash used in operating activities | -24,580 |
| Purchase of property and equipment | 104 |
| Net cash used in investing activities | -104 |
| Payments on finance leases | 10 |
| Restricted stock units withheld to cover tax obligations | 207 |
| Net cash (used in) provided by financing activities | -217 |
| Effect of foreign currency rates on cash | 6 |
| Net change in cash, cash equivalents and restricted cash | -24,895 |
| Cash, cash equivalents and restricted cash at beginning of year | 73,228 |
| Cash, cash equivalents and restricted cash at end of year | 48,333 |
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)